Home | Contact us | Disclaimer
A prospective, double-blind, placebo-controlled, safety and efficacy study
of oral ELND005 in moderate-to-severe AD patients

Study Design

• Patient population: 400 moderate-to-severe AD patients with at least moderate levels of
• 12-week treatment phase
• First patient dosed in November 2012
• Status: COMPLETED [Link to Press Release]

Primary Outcome Measures

• Changes from baseline in NPI-C combined agitation and aggression subscore

For more information on this trial, please visit: Clinical Trials
or visit www.harmonyadstudy.com.
© 2015 Transition Therapeutics Inc.